NASDAQ:TXMD

TherapeuticsMD Stock Forecast, Price & News

$1.24
+0.04 (+2.92 %)
(As of 06/24/2021 11:52 AM ET)
Add
Compare
Today's Range
$1.21
$1.26
50-Day Range
$1.02
$1.39
52-Week Range
$1.00
$2.75
Volume33,413 shs
Average Volume11.26 million shs
Market Capitalization$485.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92
30 days | 90 days | 365 days | Advanced Chart
Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD logo

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

644th out of 2,105 stocks

Pharmaceutical Preparations Industry

316th out of 832 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

Is TherapeuticsMD a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TherapeuticsMD stock.
View analyst ratings for TherapeuticsMD
or view top-rated stocks.

What stocks does MarketBeat like better than TherapeuticsMD?

Wall Street analysts have given TherapeuticsMD a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TherapeuticsMD wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for TherapeuticsMD
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings results on Thursday, May, 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm had revenue of $19.87 million for the quarter, compared to the consensus estimate of $20.22 million.
View TherapeuticsMD's earnings history
.

How has TherapeuticsMD's stock price been impacted by Coronavirus (COVID-19)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD stock has decreased by 18.8% and is now trading at $1.2350.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TXMD?

4 Wall Street analysts have issued 12 month target prices for TherapeuticsMD's shares. Their forecasts range from $1.20 to $10.00. On average, they anticipate TherapeuticsMD's share price to reach $5.07 in the next year. This suggests a possible upside of 310.3% from the stock's current price.
View analysts' price targets for TherapeuticsMD
or view top-rated stocks among Wall Street analysts.

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 50, Pay $1.22M)
  • Dr. Brian A. Bernick, Co-Founder & Chief Scientific Officer (Age 53, Pay $96.61k)
  • Mr. Edward J. Borkowski CPA, M.B.A., CPA, MBA, Exec. VP of Operations (Age 63, Pay $877.19k)
  • Mr. John C. K. Milligan IV, Chief Exec. Officer of VitaCare Prescription Services (Age 59, Pay $796.28k)
  • Mr. James C. D'Arecca, Chief Financial Officer (Age 50)
  • Mr. Michael Donegan, Chief Accounting Officer & VP of Fin. (Age 53)
  • Mr. Adam Miller, Chief Information Officer (Age 38)
  • Nichol L. Ochsner, VP of Investor Relations
  • Mr. Marlan D. Walker, Gen. Counsel (Age 45)
  • Mr. John Knighton, Chief Compliance Officer (Age 42)

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.02%), Price T Rowe Associates Inc. MD (4.66%), Morgan Stanley (1.86%), Geode Capital Management LLC (1.41%), Ameriprise Financial Inc. (1.21%) and Northern Trust Corp (0.95%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Edward Borkowski, Group L P Column, Jane F Barlow, John CK Iv Milligan, Marlan D Walker, Michael C Donegan, Robert G Finizio and Tommy G Thompson.
View institutional ownership trends for TherapeuticsMD
.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Rubric Capital Management LP, Laurion Capital Management LP, Sanders Morris Harris LLC, Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA, Virtu Financial LLC, and Credit Suisse AG. Company insiders that have sold TherapeuticsMD company stock in the last year include Edward Borkowski, Marlan D Walker, Michael C Donegan, and Robert G Finizio.
View insider buying and selling activity for TherapeuticsMD
or view top insider-selling stocks.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, Millennium Management LLC, Geode Capital Management LLC, Citigroup Inc., Northern Trust Corp, and Goldman Sachs Group Inc.. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson.
View insider buying and selling activity for TherapeuticsMD
or or view top insider-buying stocks.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $1.24.

How much money does TherapeuticsMD make?

TherapeuticsMD has a market capitalization of $485.59 million and generates $64.87 million in revenue each year. The company earns $-183,520,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does TherapeuticsMD have?

TherapeuticsMD employs 400 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is www.therapeuticsmd.com.

Where are TherapeuticsMD's headquarters?

TherapeuticsMD is headquartered at 951 Yamato Road Suite 220, BOCA RATON FL, 33431.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.